Exelixis, Inc. (EXEL) Reports Top-Line Results From a Phase 2 Trial of Cabozantinib

November 4, 2014 4:21 PM

Exelixis, Inc. (NASDAQ: EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found